Regulus Therapeutics Stock Working Capital

RGLS Stock

USD 1.63 0.02 1.24%

Regulus Therapeutics fundamentals help investors to digest information that contributes to Regulus Therapeutics' financial success or failures. It also enables traders to predict the movement of Regulus Stock. The fundamental analysis module provides a way to measure Regulus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regulus Therapeutics stock.

	Last Reported	Projected for Next Year
Net Working Capital	19.7 M	28.7 M
Change In Working Capital	257 K	269.9 K

Net Working Capital is likely to gain to about 28.7 M in 2024. Change In Working Capital is likely to gain to about 269.9 K in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Regulus Therapeutics Company Working Capital Analysis

Regulus Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Regulus Therapeutics Working Capital

19.67 M

Most of Regulus Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regulus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Regulus Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Regulus Therapeutics is extremely important. It helps to project a fair market value of Regulus Stock properly, considering its historical fundamentals such as Working Capital. Since Regulus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Regulus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Regulus Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Accounts Payable	Long Term Debt	Short Term Investments	Total Liab	Intangible Assets	Property Plant Equipment	Current Deferred Revenue	Net Debt	Retained Earnings	Total Current Assets	Short Term Debt	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Common Stock	Net Receivables	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.9	0.36	-0.02	0.95	0.1	0.71	0.23	0.07	-0.55	0.55	0.98	0.22	0.9	0.72	-0.36	-0.48	0.21	0.35	0.55	0.64	0.41	-0.22
Total Stockholder Equity	0.9		0.23	-0.2	0.78	-0.33	0.4	0.09	-0.24	-0.68	0.21	0.9	0.19	0.76	0.44	-0.01	-0.7	0.24	0.48	0.21	0.43	0.36	-0.02
Accounts Payable	0.36	0.23		0.06	0.41	0.28	0.45	0.87	-0.25	-0.07	0.12	0.33	0.34	0.16	0.3	0.01	-0.18	0.29	0.15	0.44	0.32	0.02	-0.32
Long Term Debt	-0.02	-0.2	0.06		0.04	0.41	0.34	0.24	0.46	-0.1	0.41	-0.05	-0.51	-0.04	0.41	-0.54	0.59	-0.18	-0.31	0.3	0.25	0.11	-0.18
Short Term Investments	0.95	0.78	0.41	0.04		0.29	0.84	0.28	0.22	-0.49	0.69	0.94	0.23	0.91	0.8	-0.49	-0.37	0.07	0.28	0.71	0.64	0.28	-0.43
Total Liab	0.1	-0.33	0.28	0.41	0.29		0.68	0.3	0.72	0.34	0.74	0.09	0.07	0.2	0.57	-0.74	0.6	-0.05	-0.3	0.77	0.45	0.05	-0.43
Intangible Assets	0.71	0.4	0.45	0.34	0.84	0.68		0.4	0.59	-0.26	0.92	0.7	0.14	0.71	0.88	-0.79	0.11	0.0	0.09	0.95	0.65	0.15	-0.55
Property Plant Equipment	0.23	0.09	0.87	0.24	0.28	0.3	0.4		-0.19	-0.05	0.08	0.17	0.18	0.01	0.26	-0.07	-0.07	0.16	0.08	0.37	0.16	-0.1	-0.33
Current Deferred Revenue	0.07	-0.24	-0.25	0.46	0.22	0.72	0.59	-0.19		0.19	0.83	0.07	-0.17	0.25	0.53	-0.88	0.69	-0.19	-0.3	0.63	0.35	0.05	-0.3
Net Debt	-0.55	-0.68	-0.07	-0.1	-0.49	0.34	-0.26	-0.05	0.19		-0.16	-0.57	0.38	-0.52	-0.35	0.07	0.52	-0.18	-0.65	-0.09	-0.34	-0.34	-0.11
Retained Earnings	0.55	0.21	0.12	0.41	0.69	0.74	0.92	0.08	0.83	-0.16		0.54	-0.04	0.66	0.84	-0.93	0.33	-0.06	-0.03	0.9	0.66	0.22	-0.45
Total Current Assets	0.98	0.9	0.33	-0.05	0.94	0.09	0.7	0.17	0.07	-0.57	0.54		0.25	0.88	0.7	-0.31	-0.47	0.24	0.38	0.55	0.64	0.4	-0.17
Short Term Debt	0.22	0.19	0.34	-0.51	0.23	0.07	0.14	0.18	-0.17	0.38	-0.04	0.25		0.01	-0.14	0.18	-0.3	0.0	-0.25	0.28	-0.14	-0.37	-0.24
Net Tangible Assets	0.9	0.76	0.16	-0.04	0.91	0.2	0.71	0.01	0.25	-0.52	0.66	0.88	0.01		0.81	-0.48	-0.39	0.04	0.39	0.54	0.64	0.41	-0.31
Long Term Debt Total	0.72	0.44	0.3	0.41	0.8	0.57	0.88	0.26	0.53	-0.35	0.84	0.7	-0.14	0.81		-0.71	0.06	-0.07	0.25	0.76	0.65	0.28	-0.43
Capital Surpluse	-0.36	-0.01	0.01	-0.54	-0.49	-0.74	-0.79	-0.07	-0.88	0.07	-0.93	-0.31	0.18	-0.48	-0.71		-0.49	0.16	0.15	-0.79	-0.56	-0.19	0.45
Deferred Long Term Liab	-0.48	-0.7	-0.18	0.59	-0.37	0.6	0.11	-0.07	0.69	0.52	0.33	-0.47	-0.3	-0.39	0.06	-0.49		-0.07	-0.46	0.23	0.13	0.04	-0.04
Common Stock	0.21	0.24	0.29	-0.18	0.07	-0.05	0.0	0.16	-0.19	-0.18	-0.06	0.24	0.0	0.04	-0.07	0.16	-0.07		0.21	-0.04	0.55	0.7	0.7
Net Receivables	0.35	0.48	0.15	-0.31	0.28	-0.3	0.09	0.08	-0.3	-0.65	-0.03	0.38	-0.25	0.39	0.25	0.15	-0.46	0.21		-0.02	0.25	0.27	0.12
Short Long Term Debt	0.55	0.21	0.44	0.3	0.71	0.77	0.95	0.37	0.63	-0.09	0.9	0.55	0.28	0.54	0.76	-0.79	0.23	-0.04	-0.02		0.58	0.03	-0.56
Net Invested Capital	0.64	0.43	0.32	0.25	0.64	0.45	0.65	0.16	0.35	-0.34	0.66	0.64	-0.14	0.64	0.65	-0.56	0.13	0.55	0.25	0.58		0.83	0.06
Net Working Capital	0.41	0.36	0.02	0.11	0.28	0.05	0.15	-0.1	0.05	-0.34	0.22	0.4	-0.37	0.41	0.28	-0.19	0.04	0.7	0.27	0.03	0.83		0.49
Capital Stock	-0.22	-0.02	-0.32	-0.18	-0.43	-0.43	-0.55	-0.33	-0.3	-0.11	-0.45	-0.17	-0.24	-0.31	-0.43	0.45	-0.04	0.7	0.12	-0.56	0.06	0.49

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Regulus Therapeutics

Working Capital Over Time

Regulus Capital Surpluse

Capital Surpluse

356.47 Million

At this time, Regulus Therapeutics' Capital Surpluse is comparatively stable compared to the past year.

Based on the company's disclosures, Regulus Therapeutics has a Working Capital of 19.67 M. This is 95.38% lower than that of the Biotechnology sector and 96.35% lower than that of the Health Care industry. The working capital for all United States stocks is 98.67% higher than that of the company.

Regulus Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regulus Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regulus Therapeutics could also be used in its relative valuation, which is a method of valuing Regulus Therapeutics by comparing valuation metrics of similar companies.

Regulus Therapeutics is currently under evaluation in working capital category among its peers.

Regulus Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Regulus Therapeutics from analyzing Regulus Therapeutics' financial statements. These drivers represent accounts that assess Regulus Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Regulus Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	15.4M	47.2M	27.4M	20.9M	24.0M	22.8M
Enterprise Value	(4.1M)	20.8M	(25.9M)	3.0M	3.4M	3.2M

Regulus Fundamentals

	Return On Equity	-0.72
	Return On Asset	-0.42
	Current Valuation	18.63 M
	Shares Outstanding	65.5 M
	Shares Owned By Insiders	1.69 %
	Shares Owned By Institutions	88.29 %
	Number Of Shares Shorted	1.64 M
	Price To Earning	(0.69) X
	Price To Book	1.21 X
	Price To Sales	7.43 X
	Gross Profit	(18.41 M)
	EBITDA	(30.88 M)
	Net Income	(30.04 M)
	Cash And Equivalents	47.53 M
	Cash Per Share	3.25 X
	Total Debt	2.39 M
	Debt To Equity	0.17 %
	Current Ratio	8.82 X
	Book Value Per Share	1.32 X
	Cash Flow From Operations	(26.77 M)
	Short Ratio	3.63 X
	Earnings Per Share	(1.02) X
	Price To Earnings To Growth	(0.04) X
	Target Price	10.33
	Number Of Employees	32
	Beta	1.63
	Market Capitalization	107.42 M
	Total Asset	30.75 M
	Retained Earnings	(513.21 M)
	Working Capital	19.67 M
	Current Asset	134.26 M
	Current Liabilities	12.63 M
	Net Asset	30.75 M

About Regulus Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Regulus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regulus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regulus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Regulus Stock Analysis

When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC